Trials / Conditions / Alpha-Mannosidosis

Alpha-Mannosidosis

20 registered clinical trials studyying Alpha-Mannosidosis — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age NCT06184503	Chiesi Farmaceutici S.p.A.	—
Withdrawn	Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis NCT04031066	Chiesi Farmaceutici S.p.A.	Phase 3
Completed	Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-Mannosidosis NCT02998879	Chiesi Farmaceutici S.p.A.	Phase 2
Completed	Evaluation of Long-term Efficacy of Treatment With Lamazym NCT02478840	Zymenex A/S	Phase 3
Recruiting	UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte- NCT02254863	Joanne Kurtzberg, MD	Phase 1
Completed	Clinical Biomarkers in Alpha-mannosidosis NCT02141503	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	—
Active Not Recruiting	MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis NCT02171104	Masonic Cancer Center, University of Minnesota	Phase 2
Completed	Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients NCT01908712	Chiesi Farmaceutici S.p.A.	Phase 3
Completed	Lamazym Aftercare Study NCT01908725	Chiesi Farmaceutici S.p.A.	Phase 3
Completed	A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis NCT01681953	Zymenex A/S	Phase 3
Recruiting	Longitudinal Study of Neurodegenerative Disorders NCT03333200	University of Pittsburgh	—
Completed	Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis NCT01681940	Zymenex A/S	Phase 2
Terminated	Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders NCT01372228	Talaris Therapeutics Inc.	Phase 1 / Phase 2
Unknown	Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosi NCT01285700	Zymenex A/S	Phase 2
Completed	Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis NCT01268358	Zymenex A/S	Phase 1
Completed	Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders NCT01043640	Masonic Cancer Center, University of Minnesota	Phase 2
Completed	Longitudinal Studies of the Glycoproteinoses NCT01891422	Greenwood Genetic Center	—
Terminated	Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism NCT00668564	Masonic Cancer Center, University of Minnesota	Phase 2
Completed	The Natural History of Alpha-Mannosidosis NCT00498420	Zymenex A/S	—
Available	Expanded Access to Velmanase Alfa NCT04959240	Chiesi Farmaceutici S.p.A.	—